Literature DB >> 10553955

Ketamine stereoselectively inhibits rat dopamine transporter.

M Nishimura1, K Sato.   

Abstract

Ketamine is usually administered as a racemate, which is composed of the two isomers, S(+)-and R(-)-ketamine. Recently, we have shown that racemic ketamine at clinical relevant concentrations specifically inhibits the transporter proteins for norepinephrine, dopamine and serotonin heterologously expressed in HEK-293 cells (Nishimura, M., Sato, K., Okada, T., Yoshiya, I., Schloss, P., Shimada, S. and Tohyama, M., Ketamine inhibits monoamine transporters expressed in human embryonic kidney 293 cells. Anesthesiology, 88 (1998) 768-774). Since ketamine interacts stereoselectively with most of its targets, we now investigated whether ketamine also exhibits stereoselectivity on the monoamine transporters. Only the dopamine transporter was found to be stereoselectively inhibited with S(+)-ketamine being almost eight times more potent than R(-)-ketamine (Ki = 46.9 microM for S(+)-ketamine, 390 microM for R(-)-ketamine). In contrast, ketamine exhibited no stereoselectivity for norepinephrine and serotonin transporters.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10553955     DOI: 10.1016/s0304-3940(99)00688-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  17 in total

1.  5-HT1A and 5-HT1B receptors differentially modulate rate and timing of auditory responses in the mouse inferior colliculus.

Authors:  Lissandra Castellan Baldan Ramsey; Shiva R Sinha; Laura M Hurley
Journal:  Eur J Neurosci       Date:  2010-07-14       Impact factor: 3.386

Review 2.  Neurochemical modulators of sleep and anesthetic states.

Authors:  Christa J Van Dort; Helen A Baghdoyan; Ralph Lydic
Journal:  Int Anesthesiol Clin       Date:  2008

3.  Novel psychoactive substances of interest for psychiatry.

Authors:  Fabrizio Schifano; Laura Orsolini; G Duccio Papanti; John M Corkery
Journal:  World Psychiatry       Date:  2015-02       Impact factor: 49.548

4.  Cortical glutamate-dopamine interaction and ketamine-induced psychotic symptoms in man.

Authors:  Sargo Aalto; Jouni Ihalainen; Jussi Hirvonen; Jaana Kajander; Harry Scheinin; Heikki Tanila; Kjell Någren; Harry Vilkman; Lars L Gustafsson; Erkka Syvälahti; Jarmo Hietala
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

5.  Effects of Ketamine and Ketamine Metabolites on Evoked Striatal Dopamine Release, Dopamine Receptors, and Monoamine Transporters.

Authors:  Adem Can; Panos Zanos; Ruin Moaddel; Hye Jin Kang; Katinia S S Dossou; Irving W Wainer; Joseph F Cheer; Douglas O Frost; Xi-Ping Huang; Todd D Gould
Journal:  J Pharmacol Exp Ther       Date:  2016-07-28       Impact factor: 4.030

Review 6.  Dopamine transporter imaging with [(123)I]FP-CIT SPECT: potential effects of drugs.

Authors:  Jan Booij; Paul Kemp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-30       Impact factor: 9.236

7.  The Prodrug 4-Chlorokynurenine Causes Ketamine-Like Antidepressant Effects, but Not Side Effects, by NMDA/GlycineB-Site Inhibition.

Authors:  Panos Zanos; Sean C Piantadosi; Hui-Qiu Wu; Heather J Pribut; Matthew J Dell; Adem Can; H Ralph Snodgrass; Carlos A Zarate; Robert Schwarcz; Todd D Gould
Journal:  J Pharmacol Exp Ther       Date:  2015-08-11       Impact factor: 4.030

Review 8.  Ketamine : from medicine to misuse.

Authors:  Kim Wolff; Adam R Winstock
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

9.  Effects of anaesthetics on the loss of nigrostriatal dopaminergic neurons by 6-hydroxydopamine in rats.

Authors:  K P Datla; V Zbarsky; D T Dexter
Journal:  J Neural Transm (Vienna)       Date:  2005-08-05       Impact factor: 3.850

10.  The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor.

Authors:  Bryan L Roth; Simon Gibbons; Warunya Arunotayanun; Xi-Ping Huang; Vincent Setola; Ric Treble; Les Iversen
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.